Table 5.
Main findings of clinical trials investigating circulating asprosin levels and correlations in obstetrics and gynecology.
| Citation | Cohort | Target population (Study group) | n, gender | Main finding & Correlations |
|---|---|---|---|---|
| Alan et al. (86) | PCOS cross-sectional study |
PCOS | 156 females PCOS (n = 78) Healthy controls (n = 78) |
⇑ Serum asprosin in PCOS than in healthy controls. Asprosin levels in positive correlation with HOMA-IR, BMI, free androgen index (FAI), and high sensitivity C-reactive protein (hs-CRP). |
| Chang et al. (87) | PCOS (18-34 y) | 600 females PCOS (n = 444) Healthy controls (n = 156) |
No difference of serum asprosin levels between PCOS females and the healthy controls. | |
| Deniz et al. (88) | Case-control study | PCOS | 60 participants PCOS (n = 30) Healthy controls (n = 30) |
⇑ Blood asprosin in PCOS patients compared to normal control subjects. |
| Jiang et al. (89) | PCOS | 170 women PCOS (n = 93) Healthy controls (n = 77) |
⇓ asprosin level slightly in PCOS women with hyperandrogenism or IR compared to the non-hyperandrogenism, and non-IR control groups compared to healthy controls. A negative correlation between serum asprosin and BMI, HOMA-IR, and TG. |
|
| Baykus et al. (90) | Females with pathological pregnancies (18-35 y) | 179 pregnant women GDM (n = 30) PE (n = 30) Severe PE (n = 30) IUGR (n = 30) MF (n = 29) healthy pregnant (n = 30) |
⇑ Newborn cord blood & maternal blood asprosin in GDM, PE, SPE, and MF pregnant women compared to healthy pregnant women. | |
| Zhong et al. (91) | Nested case-control study | Early diagnosed GDM (18-40 y) | 80 pregnant women GDM pregnant women (n = 40) NGT controls (n = 40) |
⇑ Plasma asprosin in pregnant females suffering from GDM and their offspring ⇑ Plasma asprosin in umbilical cord of neonates of GDM group than in NGT group. |
| Behrasi et al. (92) | Maternal obesity & Excessive gestational weight gain (EGWG) | 60 women Pregnant women with normal weight (n = 30) Pregnant women with EGWG (n = 30) |
⇑ umbilical cord blood asprosin levels were significantly higher in EGWG group compared to normal weight control group. No difference in maternal asprosin levels between both groups. |
|
| Hoffmann et al. (22) | Pregnant women with obesity/GDM | 247 pregnant females | ⇑ Maternal and fetal plasma asprosin concentrations in non-smoking obese and normal-weight mothers with GDM. A positive correlation between maternal insulin levels and placental asprosin in GDM patients. Direct correlation between maternal plasma asprosin amount and the number of exercises per week during pregnancy. |
|
| Leonard (93) | Observational study | Pre-menopausal women (Trained 201–825 min/week) |
Healthy women (n = 32) Trained OC (n = 8) Trained Non-OC (n = 6) Untrained OC (n = 10) Untrained Non-OC (n = 8) |
⇓ plasma asprosin in females using OC compared to non-OC. ⇑ plasma asprosin increased in the early follicular menstrual phase group compared to the mid-luteal and late follicular group, especially in OC users whereas the non-OC in the mid-luteal phase expressed the highest level. |